Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Kadimastem

Market Cap 50.75M 0 43.83M 40.39M 37.81M 70.86M 4.82B 71.95M 477M 186M 2.35B 190M 186M 8.13B P/E Ratio 2024 *
-
P/E Ratio 2025 -2.81x
Enterprise Value 48.9M 0 42.24M 38.92M 36.43M 68.28M 4.65B 69.34M 460M 179M 2.26B 184M 180M 7.83B EV / Sales 2024 *
-
EV / Sales 2025 -
Free-Float
35.62%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-8.93% - - 17.58M
-0.35%+0.97%-15.96%-12.73% 42.96B
+3.11%+3.11%+274.29%+507.94% 31.73B
+0.22%-1.08%+14.03%-14.37% 30.22B
+1.62%-2.08%-4.36%+24.05% 28.94B
+4.09%+0.93%+10.83%+18.78% 23.87B
-1.63%+2.88%+53.73%+114.36% 13.57B
-0.40%-1.29%+6.06%+7.59% 12.96B
+1.14%+3.62% - - 13.39B
-0.74%-1.62%+105.71%+76.01% 12.2B
Average +0.71%+0.64%+55.54%+90.21% 23.31B
Weighted average by Cap. +1.02%+0.69%+54.32%+95.99%

Financials

2024 2025
Net sales - -
Net income -26.55M -0 -22.93M -21.13M -19.78M -37.07M -2.52B -37.65M -250M -97.29M -1.23B -99.65M -97.53M -4.25B -8.3M -0 -7.17M -6.61M -6.18M -11.59M -789M -11.77M -78M -30.41M -384M -31.15M -30.49M -1.33B
Net Debt 7.35M 0 6.35M 5.85M 5.47M 10.26M 698M 10.42M 69.05M 26.92M 340M 27.57M 26.99M 1.18B -1.85M -0 -1.59M -1.47M -1.38M -2.58M -175M -2.62M -17.35M -6.76M -85.4M -6.93M -6.78M -296M
Logo Kadimastem
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
11
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!